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1. INTRODUCTION {#cam41959-sec-0005}
===============

The increasing number of cancer survivors has resulted from early cancer detection and advances in cancer treatment.[1](#cam41959-bib-0001){ref-type="ref"} However, many cancer survivors also have an increased risk of secondary primary cancers (SPCs), which might be greater than the risk of primary cancers in the general population.[2](#cam41959-bib-0002){ref-type="ref"}, [3](#cam41959-bib-0003){ref-type="ref"}, [4](#cam41959-bib-0004){ref-type="ref"}, [5](#cam41959-bib-0005){ref-type="ref"}, [6](#cam41959-bib-0006){ref-type="ref"}, [7](#cam41959-bib-0007){ref-type="ref"} A recent study reported that mortality due to SPCs was higher than mortality due to first primary cancer.[8](#cam41959-bib-0008){ref-type="ref"} SPCs have been associated with genetic susceptibility,[9](#cam41959-bib-0009){ref-type="ref"}, [10](#cam41959-bib-0010){ref-type="ref"} the carcinogenic effects of cancer treatment,[11](#cam41959-bib-0011){ref-type="ref"} and the influence of behavioral risk factors such as smoking and alcohol intake.[12](#cam41959-bib-0012){ref-type="ref"}, [13](#cam41959-bib-0013){ref-type="ref"}, [14](#cam41959-bib-0014){ref-type="ref"}, [15](#cam41959-bib-0015){ref-type="ref"}, [16](#cam41959-bib-0016){ref-type="ref"}

Obesity is a well‐known risk factor for cancer in the general population including cancers of the colon, lower esophagus, kidney, gallbladder, breast, and endometrium.[17](#cam41959-bib-0017){ref-type="ref"}, [18](#cam41959-bib-0018){ref-type="ref"}, [19](#cam41959-bib-0019){ref-type="ref"}, [20](#cam41959-bib-0020){ref-type="ref"}, [21](#cam41959-bib-0021){ref-type="ref"}, [22](#cam41959-bib-0022){ref-type="ref"} In addition, several studies have reported the association between obesity and increased SPC risk at specific sites such as breast[23](#cam41959-bib-0023){ref-type="ref"} and colorectum[24](#cam41959-bib-0024){ref-type="ref"} Although the mechanisms of the linkage between obesity and cancer risk have not been fully elucidated, hormones, including sex hormones, have been associated with increased cancer risk[21](#cam41959-bib-0021){ref-type="ref"}, [25](#cam41959-bib-0025){ref-type="ref"} Therefore, it would be relevant to evaluate the correlation between obesity and cancer risk separately according to sex. Previously, we reported that obesity was associated with increased primary cancer risk[26](#cam41959-bib-0026){ref-type="ref"} and SPC risk[6](#cam41959-bib-0006){ref-type="ref"}, [27](#cam41959-bib-0027){ref-type="ref"} in Korean male survivors. These studies demonstrated that male cancer survivors who had a higher prediagnosis BMI had an increased risk of subsequent overall SPCs and that the magnitude of the association between obesity and SPC risk was stronger than that of first primary cancer risk.[27](#cam41959-bib-0027){ref-type="ref"} However, there was no study for evaluating it in female cancer survivors.

This study evaluated the association between prediagnosis BMI and SPC risk in female cancer survivors by analyzing merged data from the Korean National Health Insurance Service (NHIS) and Korea Cental Cancer Registry (KCCR). We also compared the risk of SPC in obese female cancer survivors vs the risk of first primary cancers in the general population of women.

2. METHODS {#cam41959-sec-0006}
==========

2.1. Study population {#cam41959-sec-0007}
---------------------

This study included Korean female cancer survivors, who got health examinations by the NHIS before their first cancer diagnosis during January 2002 and December 2010. As previously mentioned,[27](#cam41959-bib-0027){ref-type="ref"} the Korean NHIS is the only public health insurer in Korea, and it provides biennial health examinations, including height and weight measurements and behavioral surveys, in which 68.2% of Koreans have been participated in 2010.[28](#cam41959-bib-0028){ref-type="ref"} The KCCR is a population‐based national cancer registry that includes information on more than 95% of patients with newly diagnosed cancer in Korea.[29](#cam41959-bib-0029){ref-type="ref"}, [30](#cam41959-bib-0030){ref-type="ref"} This study was approved by the Institutional Review Board of the National Cancer Center, Korea (NCC2015‐2017) and was exempt from the requirement of informed consent because the information in these datasets had been de‐identified.

We identified 11 175 133 women who were 18 years of age or older and used the Korean NHIS at least once between 2002 and 2010. We then excluded female survivors without information on prediagnosis BMI (N* *=* *8295), who were diagnosed with thyroid cancer as the primary cancer (N* *=* *57 881) and who were dying or diagnosed with their first incidence of cancer within 1 year after baseline NHIS examination (N* *=* *146 572). Among the remaining 10 962 385 women, we selected 146 377 female cancer survivors with their first primary cancer diagnosed between 2002 and 2010. The primary endpoint of this study was a newly diagnosed SPC, defined as a cancer with a different topology using the International Classification of Diseases, Tenth Revision \[ICD‐10\] at least 2 months later than the first primary cancer.

2.2. Assessment of prediagnosis exposure and covariates {#cam41959-sec-0008}
-------------------------------------------------------

We collected health‐related information from self‐reported questionnaires including previous medical history, current health status, smoking, alcohol intake, diet, exercise, and family history. We obtained medical comorbidities, place of residence, and insurance level for evaluating about socioeconomic status using the NHIS database.

Prediagnosis information including height and weight was collected from the one follow‐up cycle data before the primary cancer diagnosis. Height and weight were measured directly by trained persons. We calculated prediagnosis BMI and divided them by WHO criteria for Asian populations. A BMI with 18.6‐22.9 kg/m^2^ was categorized as normal, 23.0‐24.9 as overweight, 25.0‐29.9 as obese, and ≥30 as severely obese.[31](#cam41959-bib-0031){ref-type="ref"}

2.3. Statistical analysis {#cam41959-sec-0009}
-------------------------

For each individual, the accumulated person‐years of risk were calculated from the date of diagnosis of the first primary cancer to the date of diagnosis of a SPC, death, or last follow‐up (31 December 2011), whichever came first. For comparing cancer incidence between female cancer survivors and the general women population, age‐standardized incidence rates (IRs) were estimated using a direct standardization method. We used Cox proportional hazards analysis for calculating age‐adjusted and multivariable‐adjusted hazard ratios (aHRs) for SPC development related to prediagnosis BMI. We performed the tests for trends using median values for BMI.

In the additional sensitivity analyses, we excluded individuals diagnosed with simultaneous primary cancers within 2 years of the first cancer diagnosis for minimizing detection bias. We also analyzed data adjusted for follow‐up time. We also stratified associations according to age at first cancer diagnosis, stage of first primary cancer (2006‐2010), smoking, location of residence, insurance level, and disability status. In addition, we assessed the BMI‐SPC risk association in survivors of an obesity‐related cancer. Here, obesity‐related cancers were defined as previously reported, dose‐response cancers with obesity (esophageal, colorectal, pancreas, and renal cancer).[24](#cam41959-bib-0024){ref-type="ref"}, [32](#cam41959-bib-0032){ref-type="ref"} In addition, obesity‐related female cancers also were defined as obesity‐related cancers, breast cancer, and endometrial cancer.

We also compared the strength of the association between BMI and risk of cancer in female cancer survivors vs general population using Cox proportional analysis. For the evaluation of first primary cancer risk, 10 816 008 women in general population who were seen by the Korean NHIS during 2002‐2010 were included and exposure variables were collected from the first health examination that occurred in the same periods. Follow‐up duration was from the date of the first health examination to the date of diagnosis of a first primary cancer, death, or last day of 2011, whichever came first. We calculated *P* values for heterogeneity using the Q statistic. To evaluate the potential impact of death as a competing risk, we used the Poisson regression method of Fine and Gray.[33](#cam41959-bib-0033){ref-type="ref"} We used SAS for statistical analysis (version 9.3; SAS Institute, Cary, NC).

3. RESULTS {#cam41959-sec-0010}
==========

3.1. Clinical characteristics of the study population {#cam41959-sec-0011}
-----------------------------------------------------

Table [1](#cam41959-tbl-0001){ref-type="table"} shows the clinical characteristics of the study population. The mean age of female cancer survivors and the total population at baseline was 56.7 years and 45.5 years, respectively. Although mean BMI was similar in both groups (23.9 in cancer survivors vs 23.0 in total population), the proportions of the obese population (BMI ≥ 25.0 kg/m^2^) were 35.2% (30.93% with 25.0‐29.9 kg/m^2^, 4.24% with ≥30.0 kg/m^2^) for cancer survivors vs 26.1% (22.83% with 25.0‐29.9 kg/m^2^, 3.29% with ≥30.0 kg/m^2^) for the total population.

###### 

Descriptive characteristics of the study population (2002‐2010)

  Characteristic                      Cancer survivors, prediagnosis (N = 146 377)   Total cohort, starting year (N = 10 962 385)                                     
  ----------------------------------- ---------------------------------------------- ---------------------------------------------- ----------- ------------ -------- -------------
  Mean age at inclusion, years (SD)   56.67                                          13.20                                                      45.48        15.27    
  Body mass index, kg/m^2^                                                                                                                                            
  Mean (SD)                           23.92                                          (3.28)                                                     23.03        (3.37)   
  \<18.5                              4958                                           3.39                                           19168.65    711 713      6.49     3356729.01
  18.6‐22.9                           54 277                                         37.08                                          210208.66   5 109 301    46.61    24053918.48
  23‐24.9                             35 664                                         24.36                                          137567.21   2 277 630    20.78    10911422.97
  25‐29.9                             45 268                                         30.93                                          175024.32   2 503 144    22.83    11938694.03
  ≥30                                 6210                                           4.24                                           23907.60    360 597      3.29     1576156.44
  Smoking status                                                                                                                                                      
  Never                               133 520                                        94.37                                          516219.76   10 034 872   94.02    47588054.11
  Former                              1970                                           1.39                                           7493.62     197 109      1.85     827942.72
  Current                             5999                                           4.24                                           22645.85    440 605      4.13     1760678.45
  Physical activity, times/wk                                                                                                                                         
  None                                94 526                                         66.6                                           367694.19   6 959 224    65.09    33396605.00
  1‐2                                 22 934                                         16.16                                          88400.65    2 027 026    18.96    9171776.37
  3‐4                                 10 792                                         7.60                                           40465.94    914 394      8.55     3993948.33
  5‐6                                 3397                                           2.39                                           12686.45    288 919      2.70     1160115.76
  7                                   10 291                                         7.25                                           39330.54    502 092      4.70     2622259.12
  Alcohol consumption, drinks/wk                                                                                                                                      
  None                                116 889                                        82.55                                          452813.03   7 532 414    71.59    36524753.81
  2                                   22 061                                         15.58                                          86591.28    2 702 027    25.68    12536983.25
  3‐4                                 1543                                           1.09                                           5771.36     210 190      2.00     742838.12
  5                                   1106                                           0.78                                           4193.93     76 747       0.73     314632.09
  Fasting serum glucose, mg/dL                                                                                                                                        
  \<100                               122 143                                        83.65                                          475212.00   9 789 904    89.42    46427368.82
  100‐125                             12 787                                         8.76                                           48081.44    677 834      6.19     3125487.46
  126‐139                             3412                                           2.34                                           12706.44    161 958      1.48     724556.68
  ≥140                                7672                                           5.25                                           28357.98    318 459      2.91     1469428.83
  Fasting serum cholesterol, mg/dL                                                                                                                                    
  \<200                               76 163                                         52.17                                          293855.24   6 718 084    61.37    31590923.91
  200‐239                             48 548                                         33.25                                          188448.25   3 065 740    28.01    14602741.86
  ≥240                                21 293                                         14.58                                          82 086.69   1 162 189    10.62    5547547.08
  Presence of disability                                                                                                                                              
  No disability                       136 534                                        93.30                                          524107.63                         
  Disability                          9803                                           6.70                                           41617.86                          
  Diabetes                            30 499                                         20.84                                          119541.19                         
  Dyslipidemia                        37 024                                         25.3                                           151566.46                         
  Osteoporosis                        3686                                           2.52                                           15076.51                          
  Heart disease                       7616                                           5.2                                            29850.23                          
  Liver disease                       35 328                                         24.14                                          137972.55                         
  Cerebrovascular disease             13 996                                         9.56                                           57541.04                          
  SEER Stage (2006‐2010)                                                                                                                                              
  Localized                           56 680                                         44.54                                          238431.26                         
  Regional                            32 880                                         25.84                                          136644.17                         
  Distant                             21 096                                         16.58                                          88597.90                          
  Unknown                             16 590                                         13.04                                          65218.14                          

SD, standard deviation.
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3.2. Age‐Standardized IRs of first primary cancers and SPCs {#cam41959-sec-0012}
-----------------------------------------------------------

Of 565 877 person‐years of follow‐up, 2222 patients developed SPCs. The most common site of SPC in female cancer survivors was the thyroid, which represented 32.76% of all SPCs, followed by cancers of the colorectum (11.16%), lung (10.40%), stomach (7.61%), and breast (5.67%) (Table [2](#cam41959-tbl-0002){ref-type="table"}).

###### 

Age‐standardized IRs of the first and second primary cancers

  Site                                                                 All       Body mass index \<25                            Body mass index ≥25                                                            
  -------------------------------------------------------------------- --------- ----------------------------------------------- --------------------- ----------------------------------------------- -------- -----------------------------------------------
  All cancers, No.                                                     146 377   2222                                            94 899                1399                                            51 478   823
  Age‐standardized IR                                                  224.77    453.89[e](#cam41959-note-0010){ref-type="fn"}   221.34                437.87[e](#cam41959-note-0010){ref-type="fn"}   232.72   577.31[e](#cam41959-note-0010){ref-type="fn"}
  Stomach, No.                                                         23 653    169                                             15 447                113                                             8206     56
  Age‐standardized IR                                                  36.48     26.44[e](#cam41959-note-0010){ref-type="fn"}    36.84                 27.29[e](#cam41959-note-0010){ref-type="fn"}    35.74    40.9[e](#cam41959-note-0010){ref-type="fn"}
  Colorectal, No.                                                      22 649    248                                             13 923                147                                             8726     101
  Age‐standardized IR                                                  33.73     40.71[e](#cam41959-note-0010){ref-type="fn"}    32.6                  38.18[e](#cam41959-note-0010){ref-type="fn"}    35.89    57.72[e](#cam41959-note-0010){ref-type="fn"}
  Liver, No.                                                           8295      102                                             4965                  63                                              3330     39
  Age‐standardized IR                                                  12.23     15.22[e](#cam41959-note-0010){ref-type="fn"}    11.76                 14.21[e](#cam41959-note-0010){ref-type="fn"}    13.24    23.72[a](#cam41959-note-0006){ref-type="fn"}
  Pancreas, No.                                                        4497      60                                              2715                  37                                              1782     23
  Age‐standardized IR                                                  7.05      6.53[e](#cam41959-note-0010){ref-type="fn"}     6.85                  6.61[e](#cam41959-note-0010){ref-type="fn"}     7.58     6.96[a](#cam41959-note-0006){ref-type="fn"}
  Lung, No.                                                            11 786    231                                             7799                  163                                             3987     68
  Age‐standardized IR                                                  18.24     41.08[e](#cam41959-note-0010){ref-type="fn"}    19.11                 44.56[e](#cam41959-note-0010){ref-type="fn"}    16.55    31[e](#cam41959-note-0010){ref-type="fn"}
  Breast, No.                                                          30 349    126                                             21 100                80                                              9249     46
  Age‐standardized IR                                                  48.18     26.19[e](#cam41959-note-0010){ref-type="fn"}    47.21                 24.94[e](#cam41959-note-0010){ref-type="fn"}    49.04    31.19[e](#cam41959-note-0010){ref-type="fn"}
  Uterine cervix, No.                                                  6925      46                                              4634                  24                                              2291     22
  Age‐standardized IR                                                  11.39     7.64[e](#cam41959-note-0010){ref-type="fn"}     11.14                 6.46[e](#cam41959-note-0010){ref-type="fn"}     11.83    9.26[d](#cam41959-note-0009){ref-type="fn"}
  Thyroid, No.                                                                   728                                                                   454                                                      274
  Age‐standardized IR                                                            192.64                                                                180.62                                                   265.74
  Lymphoma, No.                                                        3886      41                                              2553                  21                                              1333     20
  Age‐standardized IR                                                  6.15      4.86[a](#cam41959-note-0006){ref-type="fn"}     6.1                   4.28[e](#cam41959-note-0010){ref-type="fn"}     6.14     5.75[e](#cam41959-note-0010){ref-type="fn"}
  Ovary, No.                                                           4113      43                                              2746                  23                                              1367     20
  Age‐standardized IR                                                  6.61      8.34[e](#cam41959-note-0010){ref-type="fn"}     6.44                  7.51[e](#cam41959-note-0010){ref-type="fn"}     7.04     8.77[e](#cam41959-note-0010){ref-type="fn"}
  Oral cavity and pharynx/Esophagus/larynx, No.                        1894      38                                              1265                  23                                              629      15
  Age standardized IR                                                  3.05      4.67[e](#cam41959-note-0010){ref-type="fn"}     3.08                  4.82[e](#cam41959-note-0010){ref-type="fn"}     3.18     4.44[e](#cam41959-note-0010){ref-type="fn"}
  Gallbladder and other biliary, No.                                   4994      50                                              2926                  32                                              2068     18
  Age‐standardized IR                                                  7.93      6.26[e](#cam41959-note-0010){ref-type="fn"}     7.44                  5.6[e](#cam41959-note-0010){ref-type="fn"}      8.98     11.54[e](#cam41959-note-0010){ref-type="fn"}
  Uterine corpus, No.                                                  3587      49                                              2075                  31                                              1512     18
  Age‐standardized IR                                                  5.17      11.93[e](#cam41959-note-0010){ref-type="fn"}    4.36                  11.88[e](#cam41959-note-0010){ref-type="fn"}    8.16     8.02[e](#cam41959-note-0010){ref-type="fn"}
  Kidney, No.                                                          2314      37                                              1367                  24                                              947      13
  Age‐standardized IR                                                  3.44      5.66[e](#cam41959-note-0010){ref-type="fn"}     3.13                  5.78[e](#cam41959-note-0010){ref-type="fn"}     4.23     5.07[e](#cam41959-note-0010){ref-type="fn"}
  Urinary bladder, No.                                                 1421      23                                              883                   18                                              538      5
  Age‐standardized IR                                                  2.25      4.14[e](#cam41959-note-0010){ref-type="fn"}     2.21                  4.83[e](#cam41959-note-0010){ref-type="fn"}     2.34     1.52[e](#cam41959-note-0010){ref-type="fn"}
  Leukemia, No.                                                        2144      29                                              1438                  21                                              706      8
  Age‐standardized IR                                                  3.64      6.37[e](#cam41959-note-0010){ref-type="fn"}     3.57                  6.08[e](#cam41959-note-0010){ref-type="fn"}     4        9.76[e](#cam41959-note-0010){ref-type="fn"}
  Others, No.                                                          13 870    202                                             9063                  125                                             4807     77
  Age‐standardized IR                                                  22.42     48.65[e](#cam41959-note-0010){ref-type="fn"}    22.57                 47.61[e](#cam41959-note-0010){ref-type="fn"}    22.23    59.82[e](#cam41959-note-0010){ref-type="fn"}
  Obesity‐related, No.[b](#cam41959-note-0007){ref-type="fn"}          29 786    351                                             18 228                212                                             11 558   139
  Age‐standardized IR                                                  36.21     49.38[e](#cam41959-note-0010){ref-type="fn"}    34.86                 46.83[e](#cam41959-note-0010){ref-type="fn"}    39.22    67.37[e](#cam41959-note-0010){ref-type="fn"}
  Obesity‐related female, No.[c](#cam41959-note-0008){ref-type="fn"}   64 247    520                                             42 073                315                                             22 174   205
  Age‐standardized IR                                                  91.02     84.35[e](#cam41959-note-0010){ref-type="fn"}    88.91                 79.77[e](#cam41959-note-0010){ref-type="fn"}    94.63    107.85[e](#cam41959-note-0010){ref-type="fn"}

IR of cancer per 100 000 person‐years. No. indicates the number of patients with first cancer and SPC.

IR, incidence rate.

Not significant.

Includes colorectal, kidney, pancreatic, and esophageal cancers.

Includes colorectal, kidney, pancreatic, esophageal, breast, and urinary bladder cancers.

*P *\<* *0.05

*P *\<* *0.001

John Wiley & Sons, Ltd

The overall age‐standardized IR of SPCs was 453.9 occurrences per 100 000 person‐years, more than 2.02 times the risk of first primary cancers (224.8 per 100 000 person‐years; *P *\<* *0.001) (Table [2](#cam41959-tbl-0002){ref-type="table"}). In obese women (BMI ≥ 25 kg/m^2^), the age‐standardized IR of SPCs was approximately 2.5 times greater than that of the first primary cancers (577.31 vs 232.72 per 100 000 person‐years; *P *\<* *0.001). In addition, the age‐standardized IR of obesity‐related cancers was also higher for SPCs (67.37 per 100 000 person‐years) than for first primary cancer (39.22 per 100 000 person‐years; *P *\<* *0.001) in the obese population.

3.3. Associations between prediagnosis BMI and SPCs {#cam41959-sec-0013}
---------------------------------------------------

There were positive linear trends in the associations between prediagnosis BMI and overall risk of SPC, thyroid, colorectal, ovary, obesity‐related, and obesity‐related female cancers (*P* ~trend* *~\< 0.05; Table [3](#cam41959-tbl-0003){ref-type="table"}). Compared with normal BMI patients, overweight cancer survivors had higher risk of overall SPC (aHR, 1.14; 95% CI, 1.01‐1.29), pancreas (aHR, 2.21; 95% CI, 1.01‐4.85), kidney (aHR, 2.70; 95% CI, 1.08‐6.74), and obesity‐related (aHR, 1.57; 95% CI, 1.16‐2.14) cancers. Obese female cancer survivors had a higher risk of overall SPC (aHR, 1.17; 95% CI, 1.04‐1.32) and thyroid cancer (aHR, 1.41; 95% CI, 1.15‐1.73). In addition, severely obese cancer female survivors showed a higher risk of developing an overall SPC (aHR, 1.32; 95% CI, 1.06‐1.65), colorectal (aHR, 2.31; 95% CI, 1.33‐4.03), thyroid (aHR, 1.79; 95% CI, 1.24‐2.61), and obesity‐related (aHR, 2.03; 95% CI, 1.24‐3.33) cancers. The risk of development of obesity‐related female cancer as SPC also was higher in overweight and obese female cancer survivors (aHR for BMI 23.0‐24.9 kg/m^2^, 1.41; 95% CI, 1.09‐1.82, aHR for BMI 25.0‐29.9 kg/m^2^, 1.35; 95% CI, 1.05‐1.72, and aHR for BMI ≥ 30.0 kg/m^2^, 2.10; 95% CI, 1.40‐3.14, *P* ~trend* *~= 0.001). When we computed *P* ~*heterogeneity*~ for each type of SPC across the BMI categories, there were no statistically significant differences for the multivariable‐adjusted hazard ratios for SPCs across the BMI categories in female cancer survivors.

###### 

HRs of second primary cancers by prediagnosis BMI in female cancer survivors

  Site of SPC                                                          Prediagnosis BMI, kg/m^2^                                               
  -------------------------------------------------------------------- --------------------------- ----- ----------- ------------ ------------ ----------
  All, No.                                                             56                          772   571         719          104          
  Age‐adjusted HR                                                      0.82                        1     1.13        1.14         1.24         \< 0.001
  95% CI                                                               0.63‐1.08                         1.01‐1.26   1.03‐1.27    1.01‐1.53    
  Multivariable‐adjusted HR                                            0.92                        1     1.14        1.17         1.32         0.001
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.69‐1.23                         1.01‐1.29   1.04‐1.31    1.06‐1.65    
  Stomach, No.                                                         7                           58    48          50           6            
  Age‐adjusted HR                                                      1.3                         1     1.26        1.04         0.95         0.860
  95% CI                                                               0.60‐2.85                         0.86‐1.84   0.71‐1.52    0.41‐2.20    
  Multivariable‐adjusted HR                                            1.69                        1     1.31        0.97         0.64         0.263
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.76‐3.75                         0.86‐1.99   0.63‐1.49    0.23‐1.81    
  Colorectal, No.                                                      5                           75    67          84           17           
  Age‐adjusted HR                                                      0.7                         1     1.35        1.33         2.04         0.003
  95% CI                                                               0.28‐1.73                         0.97‐1.88   0.98‐1.82    1.21‐3.46    
  Multivariable‐adjusted HR                                            0.97                        1     1.37        1.23         2.31         0.018
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.39‐2.42                         0.95‐1.97   0.86‐1.76    1.33‐4.03    
  Liver, No.                                                           4                           33    26          33           6            
  Age‐adjusted HR                                                      1.22                        1     1.18        1.17         1.61         0.390
  95% CI                                                               0.43‐3.46                         0.71‐1.98   0.72‐1.90    0.67‐3.84    
  Multivariable‐adjusted HR                                            0.99                        1     1.15        1.1          1.51         0.489
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.30‐3.26                         0.66‐1.98   0.65‐1.86    0.57‐3.95    
  Pancreas, No.                                                        2                           16    19          21           2            
  Age‐adjusted HR                                                      1.22                        1     1.77        1.51         1.09         0.419
  95% CI                                                               0.28‐5.30                         0.91‐3.45   0.79‐2.90    0.25‐4.76    
  Multivariable‐adjusted HR                                            1.02                        1     2.21        1.85         1.32         0.298
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.13‐8.06                         1.01‐4.85   0.85‐4.01    0.28‐6.15    
  Lung, No.                                                            2                           103   58          63           5            
  Age‐adjusted HR                                                      0.21                        1     0.86        0.74         0.44         0.168
  95% CI                                                               0.05‐0.85                         0.62‐1.18   0.54‐1.01    0.18‐1.09    
  Multivariable‐adjusted HR                                            0.27                        1     0.91        0.73         0.45         0.205
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.07‐1.09                         0.64‐1.29   0.51‐1.05    0.17‐1.25    
  Breast, No.                                                          5                           40    35          39           7            
  Age‐adjusted HR                                                      1.5                         1     1.35        1.23         1.66         0.336
  95% CI                                                               0.59‐3.80                         0.86‐2.12   0.80‐1.91    0.74‐3.70    
  Multivariable‐adjusted HR                                            1.58                        1     1.2         1.36         2.3          0.138
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.62‐4.06                         0.71‐2.02   0.83‐2.22    1.00‐5.29    
  Uterine cervix, No.                                                  0                           17    7           20           2            
  Age‐adjusted HR                                                      0                           1     0.63        1.43         1.08         0.161
  95% CI                                                               0                                 0.26‐1.51   0.75‐2.73    0.25‐4.69    
  Multivariable‐adjusted HR                                            0                           1     0.53        1.41         0.67         0.328
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0                                 0.19‐1.47   0.68‐2.94    0.09‐5.15    
  Thyroid, No                                                          14                          255   185         235          39           
  Age‐adjusted HR                                                      0.69                        1     1.12        1.18         1.46         0.003
  95% CI                                                               0.40‐1.19                         0.93‐1.36   0.99‐1.41    1.04‐2.04    
  Multivariable‐adjusted HR                                            0.61                        1     1.23        1.41         1.8          \<0.001
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.34‐1.09                         0.99‐1.53   1.15‐1.73    1.24‐2.61    
  Lymphoma, No.                                                        0                           12    9           18           2            
  Age‐adjusted HR                                                      0                           1     1.15        1.85         1.56         0.057
  95% CI                                                               0                                 0.48‐2.72   0.89‐3.85    0.35‐6.99    
  Multivariable‐adjusted HR                                            0                           1     1.05        1.64         1.8          0.103
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0                                 0.42‐2.63   0.74‐3.65    0.39‐8.36    
  Ovary, No.                                                           1                           15    7           17           3            
  Age‐adjusted HR                                                      0.79                        1     0.72        1.42         1.87         0.169
  95% CI                                                               0.10‐5.99                         0.29‐1.76   0.71‐2.84    0.54‐6.46    
  Multivariable‐adjusted HR                                            1.2                         1     0.92        2.09         2.77         0.041
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.15‐9.41                         0.33‐2.55   0.93‐4.70    0.73‐10.43   
  Oral cavity and pharynx/Esophagus/larynx, No.                        0                           17    6           12           3            
  Age‐adjusted HR                                                      0                           1     0.54        0.85         1.6          0.488
  95% CI                                                               0                                 0.21‐1.36   0.41‐1.78    0.47‐5.45    
  Multivariable‐adjusted HR                                            0                           1     0.47        0.75         1.86         0.552
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0                                 0.17‐1.31   0.33‐1.71    0.52‐6.62    
  Gallbladder and other biliary, No.                                   1                           16    15          16           2            
  Age‐adjusted HR                                                      0.6                         1     1.4         1.14         1.08         0.728
  95% CI                                                               0.08‐4.54                         0.69‐2.83   0.57‐2.29    0.25‐4.71    
  Multivariable‐adjusted HR                                            0.95                        1     1.36        1.3          1.31         0.538
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.12‐7.38                         0.61‐3.05   0.59‐2.83    0.29‐6.01    
  Uterine corpus, No.                                                  1                           14    16          17           1            
  Age‐adjusted HR                                                      0.91                        1     1.77        1.56         0.69         0.465
  95% CI                                                               0.12‐6.91                         0.86‐3.62   0.77‐3.16    0.09‐5.23    
  Multivariable‐adjusted HR                                            0.88                        1     1.77        2.09         1.19         0.134
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.11‐6.81                         0.79‐3.99   0.95‐4.59    0.15‐9.34    
  Kidney, No.                                                          1                           8     15          11           2            
  Age‐adjusted HR                                                      1.36                        1     2.85        1.67         2.29         0.279
  95% CI                                                               0.17‐10.90                        1.21‐6.73   0.67‐4.15    0.49‐10.79   
  Multivariable‐adjusted HR                                            1.71                        1     2.7         1.28         1.98         0.692
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.21‐13.98                        1.08‐6.74   0.47‐3.52    0.40‐9.84    
  Urinary bladder, No.                                                 1                           11    6           5            0            
  Age‐adjusted HR                                                      0.88                        1     0.82        0.52         0            0.136
  95% CI                                                               0.11‐6.84                         0.30‐2.21   0.18‐1.51    0‐.          
  Multivariable‐adjusted HR                                            1.47                        1     0.8         0.56         0            0.131
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.18‐11.95                        0.26‐2.46   0.18‐1.77    0‐.          
  Leukemia, No.                                                        1                           13    7           7            1            
  Age‐adjusted HR                                                      0.89                        1     0.82        0.67         0.72         0.447
  95% CI                                                               0.12‐6.78                         0.33‐2.07   0.27‐1.67    0.10‐5.54    
  Multivariable‐adjusted HR                                            1.22                        1     0.8         0.72         1            0.583
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.16‐9.50                         0.29‐2.19   0.257‐2.00   0.13‐8.00    
  Obesity‐related, No.[c](#cam41959-note-0015){ref-type="fn"}          8                           101   103         118          21           
  Age‐adjusted HR                                                      0.82                        1     1.54        1.39         1.87         0.0014
  95% CI                                                               0.40‐1.69                         1.17‐2.03   1.06‐1.81    1.17‐2.99    
  Multivariable‐adjusted HR                                            1.02                        1     1.57        1.3          2.03         0.013
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.47‐2.21                         1.16‐2.14   0.96‐1.76    1.24‐3.33    
  Obesity‐related female, No.[d](#cam41959-note-0016){ref-type="fn"}   14                          156   154         174          31           
  Age‐adjusted HR                                                      0.97                        1     1.41        1.35         1.81         0.001
  95% CI                                                               0.56‐1.68                         1.13‐1.77   1.09‐1.67    1.23‐2.67    
  Multivariable‐adjusted HR                                            1.22                        1     1.41        1.35         2.10         0.001
  95% CI[b](#cam41959-note-0014){ref-type="fn"}                        0.69‐2.17                         1.09‐1.82   1.05‐1.72    1.40‐3.14    

No. indicates the number of patients with SPC.

BMI, body mass index; CI, confidence interval; HR, hazard ratio; SPC, secondary primary cancer.

Tests for trends were performed by assigning a median value for the BMI and treating the new variable as a continuous term in the models.

The multivariable hazard ratio model used Cox proportional analysis and adjusted age (continuous variable), smoking status, alcohol consumption frequency, physical activity times, fasting serum glucose level, fasting serum cholesterol level, comorbidity, and average insurance premium per month.

Includes colorectal, kidney, pancreatic, and esophageal cancers.

Includes colorectal, kidney, pancreatic, esophageal, breast, and urinary bladder cancers.

John Wiley & Sons, Ltd

The BMI‐SPC risk association was statistically significant in female cancer survivors without smoking history (*P* ~trend ~= 0.001), with a localized stage in the first primary cancer (*P* ~trend ~= 0.014) and an obesity‐related cancer as the first cancer (*P* ~trend* *~= 0.036, Table [4](#cam41959-tbl-0004){ref-type="table"}). In addition, the BMI‐SPC risk association was higher among cancer survivors living in metropolitan areas (aHR for BMI ≥ 30.0 kg/m^2^, 2.05; 95% CI, 1.22‐3.46; *P* ~trend* *~= 0.001).

###### 

Stratified, multivariable analysis of risk of any SPC by prediagnosis BMI in female cancer survivors

                                                                                                               Prediagnosis BMI, kg/m^2^                                                     
  ------------------------------------------------------------------------------------------------------------ --------------------------- ------------- ----------- ----------- ----------- -------
  Smoking status                                                                                                                                                                             
  Never‐smoker, No.                                                                                            53                          696           524         681         99          
  Multivariable‐adjusted HR                                                                                    0.99                        1             1.14        1.19        1.36        0.001
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.74‐1.32                   1.00‐1.29     1.05‐1.34   1.08‐1.70               
  Ever‐smoker, No.                                                                                             2                           49            30          18          2           
  Multivariable‐adjusted HR                                                                                    0.34                        1             1.28        0.81        0.65        0.976
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.08‐1.41                   0.77‐2.15     0.45‐1.44   0.16‐2.76               
  Age at first cancer diagnosis                                                                                                                                                              
  Age \< 60 y, No.                                                                                             30                          470           272         338         47          
  Multivariable‐adjusted HR                                                                                    0.95                        1             1.00        1.12        1.18        0.119
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.64‐1.42                   0.85‐1.18     0.95‐1.32   0.84‐1.67               
  Age ≥ 60 y, No.                                                                                              26                          302           299         381         57          
  Multivariable‐adjusted HR                                                                                    1.10                        1             1.19        1.103       1.29        0.186
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.73‐1.67                   1.00 ‐1.422   0.93‐1.30   0.96‐1.74               
  Stage                                                                                                                                                                                      
  Localized, No.                                                                                               17                          288           204         292         36          
  Multivariable‐adjusted HR                                                                                    0.75                        1             1.09        1.21        1.10        0.014
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.47‐1.19                   0.91‐1.30     1.03‐1.43   0.77‐1.56               
  Regional, No.                                                                                                16                          134           119         124         18          
  Multivariable‐adjusted HR                                                                                    1.71                        1             1.494       1.22        1.54        0.208
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                1.03‐2.84                   1.16‐1.92     0.95‐1.57   0.98‐2.41               
  Distance, No.                                                                                                6                           66            49          50          9           
  Multivariable‐adjusted HR                                                                                    0.74                        1             1.05        1.04        1.43        0.681
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.30‐1.83                   0.72‐1.54     0.72‐1.51   0.70‐2.92               
  Place of residence                                                                                                                                                                         
  Metropolitan area, No.                                                                                       11                          110           123         133         18          
  Multivariable‐adjusted HR                                                                                    1.33                        1             1.76        1.63        2.05        0.001
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.67‐2.66                   1.30‐2.37     1.21‐2.20   1.22‐3.46               
  City, No.                                                                                                    9                           224           142         168         30          
  Multivariable‐adjusted HR                                                                                    0.543                       1             0.957       0.982       1.573       0.167
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.27‐1.10                   0.76‐1.21     0.78‐1.23   1.05‐2.37               
  Rural county, No.                                                                                            36                          438           306         418         56          
  Multivariable‐adjusted HR                                                                                    1.01                        1             1.08        1.14        1.07        0.126
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.71‐1.44                   0.92‐1.27     0.98‐1.33   0.78‐1.46               
  Average insurance premium per month                                                                                                                                                        
  1st quarter, No.                                                                                             12                          160           135         159         26          
  Multivariable‐adjusted HR                                                                                    0.90                        1             1.27        1.2         1.46        0.039
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.50‐1.62                   1.00‐1.62     0.95‐1.52   0.95‐2.25               
  2nd quarter, No.                                                                                             17                          164           107         172         29          
  Multivariable‐adjusted HR                                                                                    1.06                        1             1.02        1.20        1.44        0.060
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.63‐1.77                   0.79‐1.31     0.95‐1.51   0.95‐2.19               
  3rd quarter, No.                                                                                             11                          175           122         134         16          
  Multivariable‐adjusted HR                                                                                    0.80                        1             1.09        0.97        0.92        0.963
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.43‐1.47                   0.85‐1.39     0.76‐1.24   0.55‐1.56               
  4th quarter, No.                                                                                             13                          170           123         168         22          
  Multivariable‐adjusted HR                                                                                    1.03                        1             1.10        1.24        1.37        0.040
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.57‐1.86                   0.86‐1.39     0.99‐1.56   0.88‐2.19               
  Presence of disability                                                                                                                                                                     
  No disability, No.                                                                                           53                          750           542         664         87          
  Multivariable‐adjusted HR                                                                                    0.90                        1             1.13        1.14        1.22        0.009
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.67‐1.21                   1.00‐1.28     1.01‐1.28   0.96‐1.56               
  Disability, No.                                                                                              3                           22            29          55          17          
  Multivariable‐adjusted HR                                                                                    1.86                        1             1.50        1.950       2.71        0.006
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.54‐6.36                   0.81‐2.79     1.13‐3.38   1.34‐5.50               
  Cancer survivors whose first cancer was obesity‐related cancer, No.[c](#cam41959-note-0021){ref-type="fn"}   11                          130           128         154         25          
  Multivariable‐adjusted HR                                                                                    1.33                        1             1.36        1.34        1.57        0.036
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.71‐2.49                   1.03‐1.79     1.03‐1.74   0.97‐2.54               
  Cancer survivors whose first cancer was obesity‐related cancer, No.[d](#cam41959-note-0022){ref-type="fn"}   31                          370           282         334         54          
  Multivariable‐adjusted HR                                                                                    1.29                                      1.16        1.13        1.34        0.148
  95% CI[b](#cam41959-note-0020){ref-type="fn"}                                                                0.88‐1.90                                 0.97‐1.34   0.95‐1.34   0.97‐1.85   

No. indicates the number of patients with SPC.

BMI, body mass index; CI, confidence interval; HR, hazard ratio; SPC, secondary primary cancer.

Tests for trends were performed by assigning a median value for the BMI and treating the new variable as a continuous term in the models.

The multivariable hazard ratio model used Cox proportional analysis and adjusted age (continuous variable), smoking status, alcohol consumption frequency, physical activity times, fasting serum glucose level, fasting serum cholesterol level, comorbidity, and average insurance premium per month.

Includes colorectal, kidney, pancreatic, and esophageal cancers.

Includes colorectal, kidney, pancreatic, esophageal, breast, and endometrial cancers.

John Wiley & Sons, Ltd

In analyses of SPC risk that allowed for death as a competing risk, subdistribution HRs for SPC were statistically significant in overweight (aHR, 1.06; 95% CI, 1.03‐1.29) and obese (aHR, 1.09; 95% CI, 1.06‐1.12) female cancer survivors (*P* ~trend* *~\< 0.001). Five‐year cumulative mortality among female cancer survivors was higher in the overweight (65.27%), obese (63.78%), and severely obese (62.90%) female cancer survivors than in the normal (66.50%) and underweight (54.87%) groups. Compared to groups with normal BMI, the severely obese survivors had a subdistribution HR for death of 1.13 (95% CI, 1.11‐1.16; *P* ~trend* *~\< 0.001).

3.4. Comparison of the association between BMI and risk of first cancer in the general population {#cam41959-sec-0014}
-------------------------------------------------------------------------------------------------

We compared the magnitude of the association between obesity and risk of SPC among female cancer survivors with the association between BMI and risk of first cancer in cancer‐free general population (Table [5](#cam41959-tbl-0005){ref-type="table"}). We included 565 877 person‐years of follow‐up in our analysis, and we documented 146 377 patients with primary cancers. Overall, the BMI‐cancer associations between BMI and first cancer risk were similar to associations between BMI and SPC risk in female cancer survivors. In the severely obese category, the aHRs for SPCs in female cancer survivors (aHR, 1.32; 95% CI, 1.06‐1.65) were similar to those with first cancers in cancer‐free general population (aHR, 1.20; 95% CI, 1.17‐1.24, *P* ~heterogeneity* *~= 0.403). In the obese category, the magnitude of the BMI‐SPC risk association was similar to the association with the first cancers (aHR, 1.17; 95% CI, 1.04‐1.31 vs aHR, 1.12; 95% CI, 1.10‐1.13, *P* ~heterogeneity* *~= 0.461).

###### 

HRs of first cancer by BMI in female cohort participants

  Site of first cancer                            Prediagnosis BMI, kg/m^2^                                                 
  ----------------------------------------------- --------------------------- ----------- ------------ ------------ ------- ----------
  All, No.                                        4958                        54 277      35 664       45 268       6 210   
  Age‐adjusted HR                                 0.67                        1           1.34         1.46         1.55    \<0.0001
  95% CI                                          0.65‐0.69                   1.32‐1.35   1.44‐1.48    1.51‐1.59            
  Multivariable‐adjusted HR                       0.83                        1           1.08         1.12         1.20    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.81‐0.86                   1.06‐1.09   1.10‐1.13    1.17‐1.24            
  Stomach, No.                                    853                         8781        5813         7297         909     
  Age‐adjusted HR                                 0.707                       1           1.312        1.397        1.35    \<0.0001
  95% CI                                          0.66‐0.76                   1.27‐1.36   1.35‐1.44    1.26‐1.45            
  Multivariable‐adjusted HR                       0.89                        1           1.04         1.05         1.03    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.82‐0.95                   1.01‐1.08   1.02‐1.08    0.96‐1.10            
  Colorectal, No.                                 596                         7629        5698         7649         1077    
  Age‐adjusted HR                                 0.57                        1           1.48         1.68         1.83    \<0.0001
  95% CI                                          0.53‐0.62                   1.43‐1.53   1.63‐1.74    1.72‐1.95            
  Multivariable‐adjusted HR                       0.72                        1           1.14         1.21         1.34    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.66‐0.79                   1.10‐1.18   1.17‐1.25    1.26‐1.43            
  Liver, No.                                      235                         2685        2045         2888         442     
  Age‐adjusted HR                                 0.65                        1           1.49         1.77         2.09    \<0.0001
  95% CI                                          0.57‐0.74                   1.40‐1.58   1.67‐1.86    1.89‐2.31            
  Multivariable‐adjusted HR                       0.72                        1           1.24         1.41         1.77    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.63‐0.83                   1.17‐1.32   1.33‐1.49    1.59‐1.96            
  Pancreas, No.                                   137                         1424        1154         1574         208     
  Age‐adjusted HR                                 0.73                        1           1.48         1.63         1.67    \<0.0001
  95% CI                                          0.61‐0.86                   1.37‐1.60   1.52‐1.75    1.44‐1.93            
  Multivariable‐adjusted HR                       0.82                        1           1.20         1.25         1.28    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.69‐0.98                   1.11‐1.30   1.16‐1.35    1.10‐1.48            
  Lung, No.                                       518                         4419        2862         3578         409     
  Age‐adjusted HR                                 0.87                        1           1.214        1.245        1.11    0.002
  95% CI                                          0.79‐0.95                   1.16‐1.27   1.19‐1.30    1.00‐1.23            
  Multivariable‐adjusted HR                       0.96                        1           0.99         0.98         0.88    0.103
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.88‐1.06                   0.95‐1.04   0.93‐1.02    0.80‐0.98            
  Breast, No.                                     903                         12 943      7254         8089         1160    
  Age‐adjusted HR                                 0.50                        1           1.27         1.33         1.47    \<0.0001
  95% CI                                          0.47‐0.54                   1.23‐1.31   1.29‐1.36    1.38‐1.56            
  Multivariable‐adjusted HR                       0.54                        1           1.17         1.17         1.33    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.503‐0.578                 1.13‐1.20   1.14‐1.21    1.25‐1.41            
  Uterine cervix, No.                             299                         2746        1589         2035         256     
  Age‐adjusted HR                                 0.79                        1           1.24         1.42         1.38    \<0.0001
  95% CI                                          0.71‐0.89                   1.17‐1.32   1.34‐1.51    1.21‐1.57            
  Multivariable‐adjusted HR                       0.93                        1           1.07         1.16         1.11    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.83‐1.06                   1.00‐1.14   1.09‐1.24    0.97‐1.27            
  Lymphoma, No.                                   140                         1458        955          1182         151     
  Age‐adjusted HR                                 0.71                        1           1.35         1.42         1.45    0.001
  95% CI                                          0.60‐0.84                   1.24‐1.46   1.34‐1.57    1.23‐1.71            
  Multivariable‐adjusted HR                       0.89                        1           1.10         1.12         1.15    0.001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.74‐1.06                   1.01‐1.20   1.03‐1.22    0.97‐1.37            
  Ovary, No.                                      160                         1551        1035         1196         171     
  Age‐adjusted HR                                 0.74                        1           1.45         1.52         1.67    \<0.0001
  95% CI                                          0.63‐0.87                   1.34‐1.57   1.40‐1.64    1.43‐1.96            
  Multivariable‐adjusted HR                       0.87                        1           1.18         1.18         1.35    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.74‐1.03                   1.09‐1.27   1.092‐1.28   1.15‐1.59            
  Oral cavity and pharynx/Esophagus/larynx, No.   94                          743         428          547          82      
  Age‐adjusted HR                                 0.92                        1           1.16         1.27         1.48    0.536
  95% CI                                          0.75‐1.14                   1.03‐1.31   1.14‐1.42    1.18‐1.86            
  Multivariable‐adjusted HR                       1.08                        1           0.94         1.00         1.12    0.896
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.86‐1.35                   0.83‐1.07   0.89‐1.13    0.88‐1.42            
  Gallbladder and other biliary, No.              144                         1547        1235         1819         249     
  Age‐adjusted HR                                 0.70                        1           1.46         1.74         1.86    \<0.0001
  95% CI                                          0.59‐0.83                   1.36‐1.58   1.63‐1.87    1.63‐2.13            
  Multivariable‐adjusted HR                       0.78                        1           1.18         1.36         1.48    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.66‐0.93                   1.09‐1.27   1.26‐1.46    1.29‐1.70            
  Uterine corpus, No.                             77                          1146        852          1225         287     
  Age‐adjusted HR                                 0.50                        1           1.68         2.24         4.060   \<0.0001
  95% CI                                          0.40‐0.62                   1.53‐1.83   2.07‐2.43    3.57‐4.62            
  Multivariable‐adjusted HR                       0.51                        1           1.44         1.81         3.37    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.40‐0.65                   1.31‐1.59   1.66‐1.98    2.94‐3.86            
  Kidney, No.                                     61                          740         566          826          121     
  Age‐adjusted HR                                 0.61                        1           1.59         2.03         2.30    \<0.0001
  95% CI                                          0.48‐0.79                   1.42‐1.77   1.84‐2.25    1.90‐2.78            
  Multivariable‐adjusted HR                       0.70                        1           1.24         1.48         1.65    \<0.0001
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.52‐0.93                   1.11‐1.39   1.33‐1.64    1.346‐2.02           
  Urinary bladder, No.                            50                          486         347          463          75      
  Age‐adjusted HR                                 0.76                        1           1.30         1.40         1.75    0.001
  95% CI                                          0.57‐1.01                   1.13‐1.50   1.23‐1.59    1.37‐2.24            
  Multivariable‐adjusted HR                       0.85                        1           1.06         1.08         1.42    0.005
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.63‐1.14                   0.92‐1.22   0.95‐1.24    1.10‐1.82            
  Leukemia, No.                                   109                         806         523          619          87      
  Age‐adjusted HR                                 0.97                        1           1.34         1.38         1.51    0.060
  95% CI                                          0.80‐1.19                   1.20‐1.49   1.24‐1.54    1.21‐1.88            
  Multivariable‐adjusted HR                       1.14                        1           1.15         1.18         1.26    0.009
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.93‐1.40                   1.02‐1.29   1.05‐1.32    1.00‐1.59            
  Others, No.                                     582                         5173        3308         4281         526     
  Age‐adjusted HR                                 0.82                        1           1.23         1.33         1.27    \<0.0001
  95% CI                                          0.76‐0.90                   1.18‐1.29   1.28‐1.39    1.16‐1.38            
  Multivariable‐adjusted HR                       1.00                        1           1.01         1.04         1.02    0.093
  95% CI[b](#cam41959-note-0026){ref-type="fn"}   0.91‐1.09                   0.96‐1.06   1.00‐1.09    0.93‐1.12            

No. indicates the number of patients with first cancer.

BMI, body mass index; CI, confidence interval; HR, hazard ratio.

Tests for trends were performed by assigning a median value for the BMI and treating the new variable as a continuous term in the models.

The multivariable hazard ratio model used Cox proportional analysis and adjusted age (continuous variable), smoking status, alcohol consumption frequency, physical activity times, fasting serum glucose level, fasting serum cholesterol level, comorbidity, and average insurance premium per month.
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4. DISCUSSION {#cam41959-sec-0015}
=============

Using the Korean female cancer survivor cohort, we demonstrated that obese female cancer survivors before first primary cancer diagnosis had a higher risk of subsequent SPC and increased risk of thyroid, colorectal, ovary, obesity‐related, and obesity‐related female cancers. In addition, the BMI‐SPC risk association was statistically significant in female cancer survivors without smoking history, with a localized first primary cancer, and who lived in a metropolitan area. However, there was no difference in the magnitude of the association between obesity and SPC risk in female cancer survivors compared to that of primary cancer risk in cancer‐free general population.

Previous studies reported that obesity is a risk factor for primary cancers, such as breast, colorectal, liver, and kidney in the general population,[17](#cam41959-bib-0017){ref-type="ref"}, [18](#cam41959-bib-0018){ref-type="ref"}, [19](#cam41959-bib-0019){ref-type="ref"}, [34](#cam41959-bib-0034){ref-type="ref"} which is consistent with our finding that obesity increased the risk of first primary cancer. In this study, we could find the significant dose‐dependent relationships between prediagnosis BMI and overall SPCs including obesity‐related, obesity‐related female, and several individual SPCs. Previous studies have identified obese patients have experienced higher recurrences in colorectal, pancreatic, prostate, and breast cancers.[35](#cam41959-bib-0035){ref-type="ref"}, [36](#cam41959-bib-0036){ref-type="ref"}, [37](#cam41959-bib-0037){ref-type="ref"}, [38](#cam41959-bib-0038){ref-type="ref"} In a cohort of over 10 000 breast cancer survivors, the HR of SPCs in overweight women was 2.23 (95% CI, 1.23‐4.05) for endometrial cancer, 1.67 (95% CI, 0.99‐2.82) for colorectal cancer, and 0.80 (95% CI, 0.28‐2.29) for ovarian cancer.[39](#cam41959-bib-0039){ref-type="ref"} In a meta‐analysis of prospective studies for excess body weight and SPC risk after breast cancer, obesity was associated with significantly increased risk of SPC of the contralateral breast (relative risk (RR), 1.37; 95% CI, 1.20‐1.57), breast (RR, 1.40; 95% CI, 1.24‐1.58), endometrium (RR, 1.96; 95% CI, 1.43‐2.70), and colorectum (RR, 1.89; 95% CI, 1.28‐2.79).[23](#cam41959-bib-0023){ref-type="ref"} In a pooled analysis of five prospective cohort studies for colorectal cancer survivors, overweight and obese survivors had an increased risk of a second obesity‐associated cancer (aHR, 1.39; 95% CI, 1.01‐1.92; aHR, 1.47; 95% CI, 1.02‐2.12, respectively) compared to survivors with normal prediagnosis BMI.[24](#cam41959-bib-0024){ref-type="ref"} In a prospective cohort study of a large Korean population, the incidence of thyroid cancer was positively associated with higher BMI in women younger than 50 years of age (HR, 1.57 for BMI ≥ 25.0 Kg/m^2^; 95% CI, 1.28‐1.92).[40](#cam41959-bib-0040){ref-type="ref"}

The mechanisms by which obesity confers an increased risk of first primary cancer or SPCs are likely to be similar. The positive association between obesity and risk of SPC in female cancer survivors could be, in a large part, explained by increased circulating estrogen, other circulating hormones, or other growth factors, or by a low‐grade chronic inflammatory state.[21](#cam41959-bib-0021){ref-type="ref"}, [41](#cam41959-bib-0041){ref-type="ref"}, [42](#cam41959-bib-0042){ref-type="ref"} Furthermore, it could be explained by additional genetic susceptibility or the carcinogenic effects due to cancer treatment. Interestingly, our study showed that higher BMI was more in female cancer survivors than in general population and the association between obesity and SPC risk among female cancer survivors was similar to that of first primary cancer risk in cancer‐free general population. These findings are different from previous results that the strength of the BMI‐cancer association was slightly stronger in male cancer survivors than in the general population.[27](#cam41959-bib-0027){ref-type="ref"} These suggest that association between obesity and risk of SPC could be different by gender. In addition, our study showed that the BMI‐SPC risk association was statistically significant in female cancer survivors without smoking history and those with a localized first primary cancer. This suggests that obesity could affect SPC in female cancer survivors who have healthier lifestyle or expect longer life expectancy.

In subgroup analyses, the HR for SPC according to prediagnosis BMI was significantly higher in female cancer survivors who did not have smoking history or who had localized primary cancer. Smoking history would be a confounding factor in this study. In addition, it could be explained by that the cancer survivors have a relatively healthier lifestyle or because early‐stage cancers might confer a greater chance for long‐term survival, these findings could inform planning for long‐term cancer survivorship programs, such as including early SPC detection.

Strengths of this study are that we could use the large‐scaled, prospective cohort with approximate 150 000 female cancer survivors, including detailed information of prediagnosis behavioral risk factors. Our study design reduced recall bias, which could be a limitation in retrospective studies of cancer survivors. Specifically, height and weight, the main variables in our study, were measured by trained persons, not based on self‐report. To our knowledge, this is the first large cohort study of female cancer survivors to show that prediagnosis BMI might affect the risk of the subsequent overall, obesity‐related, and individual SPCs.

Because this is parallel study with the previous study for male cancer survivors,[27](#cam41959-bib-0027){ref-type="ref"} we have same limitations with the previous report. First, we could not consider the effects of cancer treatment on SPCs because of lack of detailed information about cancer treatment. This study has the possibility of selection bias because we analyzed only the population with height and weight data from the NHIS. This cohort has some possibility for SPC misclassification. Therefore, we performed sensitivity analyses for adjusting this possibility, excluding patients with SPC that diagnosed within 2 years after the first cancer diagnosis, and showed that the overall trends remained similar. In addition, we excluded thyroid cancer as primary cancer because thyroid cancer in Korea has been epidemically increased because of screening and considered as overdiagnosis.[43](#cam41959-bib-0043){ref-type="ref"} In this study, we could not evaluate the effect on the changes in BMI for female survivors because of the lack of data. So, we need to consider this limitation and try to perform the further study on the changes in BMI and SPC in future.

This study demonstrated that prediagnosis obesity increased risk of overall and individual SPCs in female cancer survivors. However, the magnitude of the association between obesity and SPC risk among female cancer survivors was similar to that of first primary cancer risk in the overall cohort. These findings suggest that lifestyle modification for weight reduction should be encouraged for prevention of primary cancer and SPCs, and individualized surveillance should be supported for obese female cancer survivors. In future, more studies should be performed to explain the different BMI‐cancer associations by gender.
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